Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINERVA: Ranibizumab in CNV
NCT01840410Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Primary completion
- Nov 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of ranibizumab in choroidal neovascularization (CNV), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01840410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01840410.